NASDAQ:AMGN Amgen Q3 2026 Earnings Report $400.52 -2.46 (-0.61%) As of 01:35 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Amgen EPS ResultsActual EPSN/AConsensus EPS $5.79Beat/MissN/AOne Year Ago EPSN/AAmgen Revenue ResultsActual RevenueN/AExpected Revenue$10.05 billionBeat/MissN/AYoY Revenue GrowthN/AAmgen Announcement DetailsQuarterQ3 2026Date11/3/2026TimeAfter Market ClosesConference Call DateTuesday, November 3, 2026Conference Call Time4:30PM ETConference Call ResourcesEarnings HistoryCompany Profile Amgen Earnings HeadlinesAmgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It3 hours ago | finance.yahoo.comAmgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?October 4 at 10:14 AM | fool.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 6 at 1:00 AM | Profits Run (Ad)Amgen (AMGN) Stock Dips While Market Gains: Key FactsOctober 1, 2026 | finance.yahoo.comAmgen Inc (AMGN) Shares Surge 1.3% -- What GF Score of 87 Tells InvestorsSeptember 29, 2026 | gurufocus.comWhy Amgen's 6% Dividend Raise Masks a Tougher Road AheadSeptember 29, 2026 | 247wallst.comSee More Amgen Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Amgen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Amgen and other key companies, straight to your email. Email Address About AmgenAmgen (NASDAQ:AMGN) is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services. Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers. Through its acquisition of Horizon Therapeutics, Amgen also added therapies including Tepezza, Krystexxa and Uplizna to its portfolio. The company additionally develops and manufactures biosimilars. Founded in 1980, Amgen is headquartered in Thousand Oaks, California, and serves patients and healthcare providers in the United States and international markets. The company’s medicines are distributed across numerous global regions through commercial operations, collaborations and healthcare systems. Robert A. Bradway has served as Amgen’s chairman and chief executive officer since 2012.View Amgen ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AI Chip Demand Gives Linde a New Growth Catalyst3 Low-Rated Stocks Analysts May Be Underestimating Ahead of Q3 EarningsNVIDIA’s Record High Raises a Bigger Question About How Far the Rally Can RunMarketBeat Week in Review – 09/28 - 10/02Could Nike’s Brutal Sell-Off Finally Be Running Out of Steam?Time to Nibble on MCD Stock After it Enters Oversold Territory?Liberty Energy’s AI Power Push Has Wall Street Divided Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
